Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Jun 20, 2022 4:05pm
124 Views
Post# 34769593

What's Next

What's NextThis from Stockwatch June 15th

RepliCel expects to file 2021 financials by June 30

RepliCel Life Sciences Inc. is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 -- Management Cease Trade Orders. On May 3, 2022, the company announced that it made an application to the British Columbia Securities Commission to approve a temporary management cease trade order (MCTO) on the basis that it would be unable to file its annual financial statements, accompanying management's discussion and analysis, and required certifications for the year ended Dec. 31, 2021, on or before the prescribed filing deadline of May 2, 2022, as required by National Instrument 51-102 -- Continuous Disclosure Obligations, and NI 52-109 -- C

With this MCTO in place until June 30th I imagine along with insiders having a cease trading in place it also may include not releasing any pertinent information.

Hopefully after June 30th we may see some long awaited information as to what is going on with this company.  Let's hope it is good news after such a long wait. 
<< Previous
Bullboard Posts
Next >>